Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference

Clinical Conference to Focus on Rare Diseases

Cambridge, Massachusetts Sep 17, 2023 (<u>Issuewire.com</u>) - <u>Andarix Pharmaceuticals</u>, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to patient groups.

The <u>Clinical Trials in Rare Diseases Conference</u>. This event will explore the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.

Media Contact

Andarix Pharmaceuticals

info@andarix.com

617-957-9858

Source: Andarix Pharmaceuticals

See on IssueWire